Stellar Biotechnologies Acquires License to Clostridium Difficile Immunotherapy Technology

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX-V: KLH), announced today that the company has acquired the license to patented technology for the development of human immunotherapies against Clostridium difficile infection (“C. diff”) from the University of Guelph in Ontario, Canada.

As quoted in the press release:

The license gives Stellar exclusive rights to develop, manufacture and sell human vaccines to treat C. diff infection that derive from technology covered by Guelph patents.  The license also includes human diagnostic applications.  Specifically, the agreement covers a family of international patents and patent applications related to the cell-wall polysaccharide of C. diff named PSII.

Click here for the full press release by Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX-V: KLH)